Compare MBOT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MBOT | VRCA |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.9M | 137.3M |
| IPO Year | 2000 | 2018 |
| Metric | MBOT | VRCA |
|---|---|---|
| Price | $1.87 | $5.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $7.50 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.2M | 29.2K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $116,887.00 | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $119.77 | $94.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.60 | $0.52 |
| 52 Week High | $4.62 | $9.82 |
| Indicator | MBOT | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 42.22 |
| Support Level | $1.65 | $5.32 |
| Resistance Level | $2.21 | $6.48 |
| Average True Range (ATR) | 0.08 | 0.48 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 36.67 | 2.50 |
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.